Mesoblast Ltd., of Melbourne, Australia, said its licensee, JCR Pharmaceuticals Co. Ltd., of Ashiya, Japan, received full approval from Japanese regulators for Temcell HS injection (JR-031), an allogeneic mesenchymal stem cell product, for treating children and adults with acute graft-vs.-host disease. Read More
SHANGHAI – Zai Lab Ltd., located in the well-known Zhangjiang Hi-tech Park, has inked a deal with UCB SA, of Brussels, licensing global rights to its first large molecule asset, set to go into phase I trials in 2016. Read More
NEW DELHI – Glenmark Pharmaceuticals SA, a Swiss subsidiary of Mumbai, India-based Glenmark Pharmaceuticals Ltd., completed phase I trials in the Netherlands of BBR 830, a monoclonal antibody (MAb) that targets a class of activated immune cells that are involved in several autoimmune disorders. Read More
HONG KONG — A new peptide-based drug delivery system has been shown for the first time to enable therapeutic proteins and possibly other drugs to cross the blood-brain barrier (BBB), which may help in treating multiple sclerosis (MS) and other central nervous system (CNS) disorders such as Alzheimer’s disease and Parkinson’s disease, Korean researchers reported. Read More
SAN DIEGO – Predictions at the International Conference on Antimicrobials and Chemotherapy and the International Congress of Chemotherapy (ICAAC/ICC) 2015 annual meeting tend to be of the dire sort, warning of a return to the pre-penicillin era. So it was a pleasant exception to listen to Glaxosmithkline plc’s Rino Rappuoli brim with optimism during his plenary talk on challenges and opportunities of vaccines. Read More
LONDON – The recently published guidelines for developing biosimilars in China are yet to be tested in practice, but it is evident there are hurdles to be navigated for international pharmas, with the new rules seen as favoring local companies. Read More
